Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Associations of fractalkine receptor (CX3CR1) and CCR5 gene variants with hypertension, diabetes and atherosclerosis in chronic renal failure patients undergoing hemodialysis

  • 387 Accesses

  • 5 Citations

Abstract

Purpose

We aimed to investigate the associations of fractalkine receptor (CX3CR1) V249I, T280M and CCR5-59029 A/G gene polymorphisms in chronic renal failure (CRF) subjects undergoing hemodialysis and to evaluate possible associations of these polymorphisms with hypertension (HT), diabetes mellitus (DM) and atherosclerosis (AS).

Methods

A total of 225 CRF subjects undergoing hemodialysis and 201 healthy controls were enrolled in the study. CRF subjects were divided into three major subgroups according to comorbidities including HT (n = 127), DM (n = 65) and AS (n = 33). Genotyping was done using polymerase chain reaction–restriction fragment length polymorphism method.

Results

The II genotype and I allele frequencies of CX3CR1 V249I polymorphism were found significantly more frequent in CRF subjects, CRF subjects with DM and CRF subjects with AS compared with controls (p < 0.05 for all comparisons). G allele frequency of CCR5 polymorphism was found significantly more prevalent in CRF subjects with DM than that of controls. Further, GG genotype and G allele frequencies of CCR5 polymorphism were significantly more prevalent in CRF subjects with AS compared with controls (p < 0.05). We also explored these polymorphisms among CRF subjects with and without following comorbidities: HT, DM, AS. We found significant association between CRF subjects with HT and without HT in terms of genotype and allele frequencies of V249I polymorphism (p < 0.05). CX3CR1 T280M polymorphism was not found significantly different in none of the comparisons.

Conclusion

These data demonstrate possible associations between CX3CR1 V249I and CCR5-59029 A/G polymorphisms and/or HT, DM and AS in CRF subjects.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Levey AS, Coresh J (2012) Chronic kidney disease. Lancet 379(9811):165–180

  2. 2.

    Yilmaz M, Sari I, Bagci B, Gumus E, Ozdemir O (2015) Aldosterone synthase CYP11B2 gene promoter polymorphism in a Turkish population with chronic kidney disease. Iran J Kidney Dis 9(3):209–214

  3. 3.

    Süleymanlar G, Utaş C, Arinsoy T et al (2011) A population-based survey of Chronic REnal Disease In Turkey–the CREDIT study. Nephrol Dial Transpl 26(6):1862–1871

  4. 4.

    Silverstein DM (2009) Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol 24(8):1445–1452

  5. 5.

    Raman D, Sobolik-Delmaire T, Richmond A (2011) Chemokines in health and disease. Exp Cell Res 317(5):575–589

  6. 6.

    Segerer S, Nelson PJ, Schlöndorff D (2000) Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 11(1):152–176

  7. 7.

    Zernecke A, Shagdarsuren E, Weber C (2008) Chemokines in atherosclerosis an update. Arterioscler Thromb Vasc Biol 28(11):1897–1908

  8. 8.

    Chakravorty SJ, Cockwell P, Girdlestone J, Brooks CJ, Savage COS (2002) Fractalkine expression on human renal tubular epithelial cells: potential role in mononuclear cell adhesion. Clin Exp Immunol 129(1):150–159

  9. 9.

    Cockwell P, Chakravorty SJ, Girdlestone J, Savage CO (2002) Fractalkine expression in human renal inflammation. J Pathol 196(1):85–90

  10. 10.

    Segerer S, Hughes E, Hudkins KL, Mack M, Goodpaster T, Alpers CE (2002) Expression of the fractalkine receptor (CX3CR1) in human kidney diseases. Kidney Int 62(2):488–495

  11. 11.

    Segerer S, Mack M, Regele H, Kerjaschki D, Schlöndorff D (1999) Expression of the CC chemokine receptor 5 in human kidney diseases. Kidney Int 56(1):52–64

  12. 12.

    Anders HJ, Vielhauer V, Schlöndorff D (2003) Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 63(2):401–415

  13. 13.

    Fischereder M, Luckow B, Hocher B et al (2001) CC chemokine receptor 5 and renal-transplant survival. Lancet 357(9270):1758–1761

  14. 14.

    Sirois-Gagnon D, Chamberland A, Perron S, Brisson D, Gaudet D, Laprise C (2011) Association of common polymorphisms in the fractalkine receptor (CX3CR1) with obesity. Obesity 19(1):222–227

  15. 15.

    Ting KH, Ueng KC, Chiang WL, Chou YE, Yang SF, Wang PH (2015) Relationship of genetic polymorphisms of the chemokine, CCL5, and its receptor, CCR5, with coronary artery disease in Taiwan. Evid Based Complement Altern Med 2015:851683

  16. 16.

    Shah R, O’Neill SM, Hinkle C et al (2015) Metabolic effects of CX3CR1 deficiency in diet-induced obese mice. PLoS One 10(9):e0138317

  17. 17.

    Abdi R, Huong TTB, Sahagun-Ruiz A et al (2002) Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 13(3):754–758

  18. 18.

    American Diabetes Association (2008) Diagnosis and classification of diabetes mellitus. Diabetes Care 31(Suppl 1):S55–S60

  19. 19.

    Mancia G, De Backer G, Dominiczak A et al (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28(12):1462–1536

  20. 20.

    Eis V, Vielhauer V, Anders HJ (2004) Targeting the chemokine network in renal inflammation. Arch Immunol Ther Exp (Warsz) 52(3):164–172

  21. 21.

    Bagci B, Bagci G, Candan F, Ozdemir O, Sezgin I (2015) The protective effect of MCP-1-2518 A > G promoter polymorphism in Turkish chronic renal failure patients requiring long-term hemodialysis. Int Urol Nephrol 47(3):551–556

  22. 22.

    Sezgin I, Koksal B, Bagci G, Kurtulgan HK, Ozdemir O (2011) CCR2 polymorphism in chronic renal failure patients requiring long-term hemodialysis. Intern Med 50(21):2457–2461

  23. 23.

    Engel DR, Krause TA, Snelgrove SL et al (2015) CX3CR1 reduces kidney fibrosis by inhibiting local proliferation of profibrotic macrophages. J Immunol 194(4):1628–1638

  24. 24.

    Shikata K, Makino H (2013) Microinflammation in the pathogenesis of diabetic nephropathy. J Diabetes Investig 4(2):142–149

  25. 25.

    Courivaud C, Bamoulid J, Loupy A et al (2013) Influence of fractalkine receptor gene polymorphisms V249I-T280M on cancer occurrence after renal transplantation. Transplantation 95(5):728–732

  26. 26.

    Borkar M, Tripathi G, Sharma RK, Sankhwar SN, Agrawal S (2011) Chemokine (CCR) and fractalkine (CX3CR) receptors and end stage renal disease. Inflamm Res 60(4):399–407

  27. 27.

    Hoffmann U, Bergler T, Segerer S et al (2010) Impact of chemokine receptor CX3CR1 in human renal allograft rejection. Transpl Immunol 23(4):204–208

  28. 28.

    Cao G, Lu Y, Gao R et al (2006) Expression of fractalkine, CX3CR1, and vascular endothelial growth factor in human chronic renal allograft rejection. Transpl Proc 38(7):1998–2000

  29. 29.

    Dabrowska-Zamojcin E, Dziedziejko V, Safranow K, Kurzawski M, Domanski L, Pawlik A (2015) Association between the CX3CR1 gene V249I polymorphism and delayed kidney allograft function. Transpl Immunol 32(3):172–174

  30. 30.

    Ozdemir O, Kayatas M, Cetinkaya S et al (2015) Bcıı–RFLP profiles for serum amiloid A1 and mutated MEFV gene prevalence in chronic renal failure patients requiring long-term hemodialysis. Ren Fail 37(2):292–296

  31. 31.

    Dong L, Nordlohne J, Ge S et al (2015) T cell CX3CR1 mediates excess atherosclerotic inflammation in renal impairment. J Am Soc Nephrol. doi:10.1681/ASN.2015050540

  32. 32.

    Losito A, Kalidas K, Santoni S, Jeffery S (2003) Association of interleukin-6-174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 64(2):616–622

  33. 33.

    Yadav AK, Lal A, Jha V (2011) Association of circulating fractalkine (CX3CL1) and CX3CR1(+)CD4(+) T cells with common carotid artery intima-media thickness in patients with chronic kidney disease. J Atheroscler Thromb 18(11):958–965

  34. 34.

    Wu J, Yin RX, Lin QZ et al (2014) Two polymorphisms in the Fractalkine receptor CX3CR1 gene influence the development of atherosclerosis: a meta-analysis. Dis Markers 2014:913678

  35. 35.

    Mogensen CE (1987) Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 31(2):673–689

  36. 36.

    Zakaria E, Al-Rawi H, Ghanem NS, Elsayed NM, Rashed A (2013) Fractalkine in type 2 Egyptian diabetics with and without nephropathy. Egypt J Intern Med 25(3):133–136

  37. 37.

    Song KH, Park J, Park JH, Natarajan R, Ha H (2013) Fractalkine and its receptor mediate extracellular matrix accumulation in diabetic nephropathy in mice. Diabetologia 56(7):1661–1669

  38. 38.

    Kikuchi Y, Ikee R, Hemmi N et al (2004) Fractalkine and its receptor, CX3CR1, upregulation in streptozotocin-induced diabetic kidneys. Nephron Exp Nephrol 97(1):e17–e25

  39. 39.

    Fyhrquist F, Metsärinne K, Tikkanen I (1995) Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens 9(Suppl 5):S19–S24

  40. 40.

    Rius C, Piqueras L, González-Navarro H et al (2013) Arterial and venous endothelia display differential functional fractalkine (CX3CL1) expression by angiotensin-II. Arterioscler Thromb Vasc Biol 33(1):96–104

  41. 41.

    Martynowicz H, Janus A, Nowacki D, Mazur G (2014) The role of chemokines in hypertension. Adv Clin Exp Med 23(3):319–325

  42. 42.

    Schäfer A, Schulz C, Fraccarollo D et al (2007) The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions. Arterioscler Thromb Vasc Biol 27(1):55–62

  43. 43.

    Marasini B, Cossutta R, Selmi C et al (2005) Polymorphism of the fractalkine receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension. Clin Dev Immunol 12(4):275–279

  44. 44.

    Turner JE, Paust HJ, Steinmetz OM et al (2008) CCR5 deficiency aggravates crescentic glomerulonephritis in mice. J Immunol 181(9):6546–6556

  45. 45.

    Lee DH, Park MH, Hwang CJ et al (2015) CCR5 deficiency increased susceptibility to lipopolysaccharide-induced acute renal injury. Arch Toxicol. doi:10.1007/s00204-015-1530-1539

  46. 46.

    Cha RH, Yang SH, Kim HS et al (2009) Genetic interactions between the donor and the recipient for susceptibility to acute rejection in kidney transplantation: polymorphisms of CCR5. Nephrol Dial Transpl 24(9):2919–2925

  47. 47.

    Krichen H, Khazen D, Sfar I et al (2011) Genetic polymorphisms of inflammatory molecules in Tunisian kidney transplantation. Transpl Proc 43(2):433–436

  48. 48.

    Hoffmann S, Park J, Jacobson LM et al (2004) Donor genomics influence graft events: the effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. Kidney Int 66(4):1686–1693

  49. 49.

    Yadav AK, Kumar V, Dutta P, Bhansali A, Jha V (2014) Variations in CCR5, but not HFE, ELMO1, or SLC12A3, are associated with susceptibility to kidney disease in north Indian individuals with type 2 diabetes. J Diabetes 6(6):547–555

  50. 50.

    Mlynarski WM, Placha GP, Wolkow PP, Bochenski JP, Warram JH, Krolewski AS (2005) Risk of diabetic nephropathy in type 1 diabetes is associated with functional polymorphisms in RANTES receptor gene (CCR5): a sex-specific effect. Diabetes 54(11):3331–3335

  51. 51.

    Prasad P, Tiwari AK, Kumar KP et al (2007) Association of TGFβ1, TNFα, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med Genet 8(1):20

Download references

Author information

Correspondence to Binnur Bagci.

Ethics declarations

Conflict of interest

All of the authors of the current study declare that they have no conflict of interest.

Ethical approval

Local ethics committee approval was obtained from Clinical Research Ethics Committee of Cumhuriyet University, Sivas, Turkey. All procedures performed in the current study have been done in accordance with the ethical standards of the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

All subjects and control subjects gave a written informed consent to participate in the current study.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bagci, B., Bagci, G., Huzmeli, C. et al. Associations of fractalkine receptor (CX3CR1) and CCR5 gene variants with hypertension, diabetes and atherosclerosis in chronic renal failure patients undergoing hemodialysis. Int Urol Nephrol 48, 1163–1170 (2016). https://doi.org/10.1007/s11255-016-1293-0

Download citation

Keywords

  • Chronic renal failure
  • CCR5
  • CX3CR1
  • Hypertension
  • Diabetes mellitus
  • Atherosclerosis
  • Polymorphism